Hashimoto encephalopathy in the 21st century
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 29, 2019
- Accepted in final form August 2, 2019
- First Published December 27, 2019.
Article Versions
- Previous version (December 27, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Simone Mattozzi, MD,
- Lidia Sabater, PhD,
- Domingo Escudero, MD, PhD,
- Helena Ariño, MD, PhD,
- Thais Armangue, MD, PhD,
- Mateus Simabukuro, MD,
- Takahiro Iizuka, MD,
- Makoto Hara, MD,
- Albert Saiz, MD, PhD,
- Stefano Sotgiu, MD,
- Josep Dalmau, MD, PhD and
- Francesc Graus, MD, PhD
- Simone Mattozzi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lidia Sabater, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Domingo Escudero, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Helena Ariño, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thais Armangue, MD, PhD,
NONE
NONE
I received speaker honnoraria from Novartis (not related to this study)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I received research support from Instituto Carlos III (PI18/00486) and Govern de la Generalitat de Catalunya (SLT006/17/00362)
NONE
I received research support from Mutua Madrilena Fundation AP162572016 and La Marato de TV3 foundation (263/C/2014)
NONE
NONE
NONE
NONE
NONE
NONE
- Mateus Simabukuro, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Takahiro Iizuka, MD,
NONE
NONE
NONE
(1)Current Treatment Options in Neurology, editorial board member,from 2013, (2) Rinsho Shinkeigaku (Clinical Neurology), editorial board member, from 2013.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Iizuka received a grant from The Japan Epilepsy Research Foundation (JERF TENKAN 17002).
NONE
NONE
NONE
NONE
NONE
NONE
- Makoto Hara, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Albert Saiz, MD, PhD,
NONE
NONE
compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd, Novartis, and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefano Sotgiu, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Josep Dalmau, MD, PhD and
NONE
NONE
NONE
Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate
Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.
NONE
NONE
Advance Medical
NONE
NONE
NONE
NONE
-NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -ERA-NET Neuron
NONE
Safra Foundation Sage therapeutics Cellex Foundation La Caixa Health Foundation
NONE
NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun
Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests
NONE
NONE
NONE
- Francesc Graus, MD, PhD
NONE
NONE
NONE
member of the editorial Board of Lancet neurology since 2002 Associate Editor of MedLink Neurology
use of IgLON5 as a diagnostic test.
Dr. Graus receives royalties from licensing fees to Euroimmun for the use of IgLON5 as a diagnostic test.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuroimmunology Program (S.M., L.S., H.A., T.A., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer, Barcelona, Spain; Department of Medical, Surgical and Experimental Medicine (S.M., S.S.), University of Sassari, Italy; Service of Neurology (D.E., A.S.), Hospital Clinic, and Pediatric Neuroimmunology Unit (T.A.), Neurology Department, Sant Joan de Déu Children's Hospital, University of Barcelona, Spain; Neurology Division (M.S.), Hospital das Clínicas, São Paulo University, Brazil; Department of Neurology (T.I.), Kitasato University School of Medicine, Sagamihara; Division of Neurology (M.H.), Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; and Institució Catalana de Recerca i Estudis Avançats (J.D.), Barcelona, Spain.
- Correspondence
Dr. Graus francesc.graus{at}idibaps.org
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Author response: Hashimoto encephalopathy in the 21st century
- Francesc Graus, Emeritus professor, Institut d'Investigació Biomèdica August Pi i Sunyer(IDIBAPS) (Barcelona, Spain)
- Josep O. Dalmau, Director, Neuroimmunology laboratory, Institut d'Investigació Biomèdica August Pi i Sunyer(IDIBAPS) (Barcelona, Spain)
Submitted September 18, 2020 - Reader response: Hashimoto encephalopathy in the 21st century
- Makoto Yoneda, Dean and Professor, Faculty of Nursing and Social Welfare Sciences, Fukui Prefectural University (Fukui, Japan)
- Akiko Matsunaga, Staff, Faculty of Nursing and Social Welfare Sciences, Fukui Prefectural University (Fukui, Japan)
- Masamichi Ikawa, Senior Assistant Professor, Department of Advanced Medicine for Community Healthcare, Faculty of Medical Sciences, University of Fukui (Fukui, Japan)
Submitted September 10, 2020 - Author response: Hashimoto encephalopathy in the 21st century
- Francesc Graus, MD, Neuroimmunology Program, Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS) (Barcelona, Spain)
- Josep Dalmau, MD, Neuroimmunology Program, Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS) (Barcelona, Spain)
Submitted January 29, 2020 - Reader response: Hashimoto encephalopathy in the 21st century
- Khichar Shubhakaran, Professor and Head Neurology, Dr. S.N. Medical College (Jodhpur, India)
Submitted January 17, 2020
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.